KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Non-Current Assets (2016 - 2026)

Palvella Therapeutics has reported Non-Current Assets over the past 10 years, most recently at $22.1 million for Q4 2022.

  • Quarterly Non-Current Assets fell 14.92% to $22.1 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $91.4 million through Dec 2022, down 14.82% year-over-year, with the annual reading at $22.1 million for FY2022, 14.92% down from the prior year.
  • Non-Current Assets was $22.1 million for Q4 2022 at Palvella Therapeutics, up from $20.6 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $29.3 million in Q4 2020 and troughed at $4.8 million in Q3 2018.
  • The 5-year median for Non-Current Assets is $24.4 million (2022), against an average of $20.0 million.
  • Year-over-year, Non-Current Assets plummeted 57.7% in 2018 and then surged 337.72% in 2019.
  • A 5-year view of Non-Current Assets shows it stood at $6.0 million in 2018, then surged by 337.72% to $26.1 million in 2019, then grew by 12.29% to $29.3 million in 2020, then dropped by 11.45% to $25.9 million in 2021, then fell by 14.92% to $22.1 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Non-Current Assets are $22.1 million (Q4 2022), $20.6 million (Q3 2022), and $23.4 million (Q2 2022).